title: A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer.
authors.affiliation: 1 Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, The University of Colorado School of Medicine , Aurora, Colorado.
authors.forename: Joshua
authors.initials: J
authors.lastname: Klopper
authors.forename: Madeleine
authors.initials: M
authors.lastname: Kane
authors.forename: Antonio
authors.initials: A
authors.lastname: Jimeno
authors.forename: Sharon
authors.initials: S
authors.lastname: Sams
authors.forename: Jena
authors.initials: J
authors.lastname: French
authors.forename: Laura
authors.initials: L
authors.lastname: Pike
authors.forename: Kenneth
authors.initials: K
authors.lastname: Tompkins
authors.forename: Bryan
authors.initials: B
authors.lastname: Haugen
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000188:drug therapy*; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene